Registered title, quoted from ClinicalTrials.gov
A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07758491, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically and/or cytologically confirmed peripheral T-cell lymphoma or cutaneous T-cell lymphoma;
Inclusion criterion 3
Have received radiotherapy within 4 weeks prior to the first dose;
Exclusion criterion 2
Have received other anti-tumor drug therapy within 3 weeks or within 5 half-lives of the anti-tumor drug prior to the first dose;
Exclusion criterion 3
Have previously received any therapy targeting the TRBC1 antigen or any antibody-drug conjugate with MMAE payload;
Exclusion criterion 5
Have received autologous stem cell transplantation within 3 months prior to the first dose;
Exclusion criterion 6
Have received high-dose systemic vitamin A therapy (daily dose >15,000 IU [i.e., 5,000 mcg]) within 3 weeks prior to the first dose of study drug;
Exclusion criterion 9
Have received oral retinoid drugs for any indication within 3 weeks prior to the first dose;
Exclusion criterion 11
Have adverse reactions from prior treatments that have not recovered to CTCAE v5.0 Grade ≤1 (excluding alopecia and anemia) prior to the first dose;
Exclusion criterion 12
ECOG performance status of 0 or 1;
Inclusion criterion 6
Have a history of other malignancies within 5 years prior to the first dose;
Exclusion criterion 8
Are pregnant or breastfeeding;
Exclusion criterion 21
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07758491, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form, understand the study, are willing to comply with and have the ability to complete all trial procedures;
- Age 18-75 years (inclusive), any gender;
- Histologically and/or cytologically confirmed peripheral T-cell lymphoma or cutaneous T-cell lymphoma;
- Relapsed or refractory lymphoma after at least one prior line of therapy;
- Able to provide tumor tissue specimens;
- ECOG performance status of 0 or 1;
- Expected survival ≥3 months;
- Have at least one measurable tumor lesion;
- Adequate cardiac, bone marrow, liver, renal function;
Exclusion Criteria:
- Have received a live vaccine within 3 months prior to the first dose;
- Have received radiotherapy within 4 weeks prior to the first dose;
- Have received other anti-tumor drug therapy within 3 weeks or within 5 half-lives of the anti-tumor drug prior to the first dose;
- Have undergone major surgery within 4 weeks prior to the first dose;
- Have previously received any therapy targeting the TRBC1 antigen or any antibody-drug conjugate with MMAE payload;
- Have received autologous stem cell transplantation within 3 months prior to the first dose;
- Have previously received allogeneic stem cell transplantation;
- Have a history of other malignancies within 5 years prior to the first dose;
- Have received high-dose systemic vitamin A therapy (daily dose >15,000 IU [i.e., 5,000 mcg]) within 3 weeks prior to the first dose of study drug;
- Have any condition requiring systemic treatment with corticosteroids (>20 mg/day prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose;
- Have received oral retinoid drugs for any indication within 3 weeks prior to the first dose;
- Have adverse reactions from prior treatments that have not recovered to CTCAE v5.0 Grade ≤1 (excluding alopecia and anemia) prior to the first dose;
- Presence or history of central nervous system lymphoma, leptomeningeal disease, or spinal cord compression;
- Have a history of severe allergic reactions or are allergic to the investigational drug;
- Have experienced a clinically significant cardiac disease within 6 months before the first dose;
- Have uncontrolled systemic diseases assessed by the investigator, including diabetes, hypertension, pulmonary fibrosis, interstitial lung disease, etc.;
- Known history of Hepatitis C or chronic active Hepatitis B;
- Clinically uncontrolled diseases such as diabetes mellitus, thyroid disease, or other severe systemic diseases requiring systemic treatment;
- Active or progressive infection requiring systemic therapy within 2 weeks prior to the first dose;
- Known or suspected active autoimmune disease requiring systemic therapy within 2 years prior to the first dose;
- Are pregnant or breastfeeding;
Quoted from ClinicalTrials.gov, NCT07758491, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07758491, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.